Scientific Publications Search Search Author Release Date Research Group Search Sort by RelevanceFrom A-ZAuthored onDate/Time RangeRelease date Order AscDesc Beule, Dieter Dr. (3) Cakmak-Görür, Nese Dr. (1) Daniel, Peter Prof. Dr. (2) Dhamodaran, Arunraj (1) Gerhardt, Holger Prof. Dr. (1) Hübner, Norbert Prof. Dr. (1) Kammertöns, Thomas Dr. (6) Kopp, Joachim Dr. (2) Kunz, Severine Dr. (1) Leisegang, Matthias Prof. Dr. rer. nat. (4) Lorenz, Felix Dr. (1) Marko, Lajos Dr. (1) Patone, Giannino Dr. (1) Pezzutto, Antonio Prof. Dr. (3) Poncette, Lucia (2) Rhein, Simone Dr. (1) Siffrin, Volker (1) Uckert, Wolfgang Prof. Dr. (5) Willimsky, Gerald Dr. (4) (-) Blankenstein, Thomas Prof. Dr. (20) 1992 (4) 1993 (7) 1994 (5) 1995 (8) 1996 (6) 1997 (9) 1998 (9) 1999 (2) 2000 (8) 2001 (5) 2002 (5) 2003 (9) 2004 (8) 2005 (10) 2006 (1) 2007 (5) 2008 (5) 2009 (2) 2010 (7) (-) 2011 (5) 2012 (6) 2013 (11) 2014 (3) (-) 2015 (3) 2016 (4) (-) 2017 (6) 2018 (4) (-) 2019 (6) 2021 (4) 2022 (6) 2023 (4) 2024 (2) Bioinformatics and Omics Data Science (1) Biology of Malignant Lymphomas (16) Cancer Genetics and Cellular Stress Responses (1) Genetics and Genomics of Cardiovascular Diseases (2) Integrative Vascular Biology (1) (-) Molecular Immunology and Gene Therapy (20) Proteome Dynamics (1) Structural Biology of Membrane-Associated Processes (1) Systems Biology of Gene Regulatory Elements (1) Translational Bioinformatics (3) 20 Results: Active Filter: Blankenstein, Thomas Prof. Dr.Molecular Immunology and Gene Therapy2011201520172019 Sort: Result score Newest to oldest Oldest to newest January 15, 2011 / Int J Cancer Tumor rejection by local interferon gamma induction in established tumors is associated with blood vessel destruction and necrosis D. Briesemeister D. Sommermeyer C. Loddenkemper R. Loew W. Uckert T. Blankenstein T. Kammertoens April 01, 2011 / Gene Ther Allogeneic gene-modified tumor cells (RCC-26/IL-7/CD80) as a vaccine in patients with metastatic renal cell cancer: a clinical phase-I study J. Westermann A. Floercken G. Willimsky A. van Lessen J. Kopp A. Takvorian K. Joehrens A. Lukowsky C. Schoenemann B. Sawitzki H. Pohla R. Frank B. Doerken D.J. Schendel T. Blankenstein A. Pezzutto November 27, 2019 / BMC Med Genomics Identification and ranking of recurrent neo-epitopes in cancer E. Blanc M. Holtgrewe A. Dhamodaran C. Messerschmidt G. Willimsky T. Blankenstein D. Beule January 02, 2019 / J Clin Invest Effective NY-ESO-1-specific MHC II-restricted T cell receptors from antigen-negative hosts enhance tumor regression L. Poncette X. Chen F.K.M. Lorenz T. Blankenstein October 15, 2017 / Clin Cancer Res T cell receptors for clinical therapy: in vitro assessment of toxicity risk A. Kunert M. Obenaus C.H.J. Lamers T. Blankenstein R. Debets December 15, 2017 / Int J Cancer The immune system prevents recurrence of transplanted but not autochthonous antigenic tumors after oncogene inactivation therapy K. Anders O. Kershaw L. Larue A.D. Gruber T. Blankenstein February 01, 2017 / Canc Immunol Res Tumor-infiltrating merkel cell polyomavirus-specific T cells are diverse and associated with improved patient survival N.J. Miller C.D. Church L. Dong D. Crispin M.P. Fitzgibbon K. Lachance L. Jing M. Shinohara I. Gavvovidis G. Willimsky M. McIntosh T. Blankenstein D.M. Koelle P. Nghiem July 28, 2011 / Blood The only proposed T-cell epitope derived from the TEL-AML1 translocation is not naturally processed J. Popovic L.P. Li P.M. Kloetzel M. Leisegang W. Uckert T. Blankenstein November 01, 2011 / Eur J Immunol Visualizing the dynamic of adoptively transferred T cells during the rejection of large established tumors J. Charo C. Perez C. Buschow A. Jukica M. Czeh T. Blankenstein December 13, 2011 / Canc Cell Oncogene-targeting T cells reject large tumors while oncogene inactivation selects escape variants in mouse models of cancer K. Anders C. Buschow A. Herrmann A. Milojkovic C. Loddenkemper T. Kammertoens P. Daniel H. Yu J. Charo T. Blankenstein Pagination Current page 1 Page 2 Next page Next › Last page Last »
January 15, 2011 / Int J Cancer Tumor rejection by local interferon gamma induction in established tumors is associated with blood vessel destruction and necrosis D. Briesemeister D. Sommermeyer C. Loddenkemper R. Loew W. Uckert T. Blankenstein T. Kammertoens
April 01, 2011 / Gene Ther Allogeneic gene-modified tumor cells (RCC-26/IL-7/CD80) as a vaccine in patients with metastatic renal cell cancer: a clinical phase-I study J. Westermann A. Floercken G. Willimsky A. van Lessen J. Kopp A. Takvorian K. Joehrens A. Lukowsky C. Schoenemann B. Sawitzki H. Pohla R. Frank B. Doerken D.J. Schendel T. Blankenstein A. Pezzutto
November 27, 2019 / BMC Med Genomics Identification and ranking of recurrent neo-epitopes in cancer E. Blanc M. Holtgrewe A. Dhamodaran C. Messerschmidt G. Willimsky T. Blankenstein D. Beule
January 02, 2019 / J Clin Invest Effective NY-ESO-1-specific MHC II-restricted T cell receptors from antigen-negative hosts enhance tumor regression L. Poncette X. Chen F.K.M. Lorenz T. Blankenstein
October 15, 2017 / Clin Cancer Res T cell receptors for clinical therapy: in vitro assessment of toxicity risk A. Kunert M. Obenaus C.H.J. Lamers T. Blankenstein R. Debets
December 15, 2017 / Int J Cancer The immune system prevents recurrence of transplanted but not autochthonous antigenic tumors after oncogene inactivation therapy K. Anders O. Kershaw L. Larue A.D. Gruber T. Blankenstein
February 01, 2017 / Canc Immunol Res Tumor-infiltrating merkel cell polyomavirus-specific T cells are diverse and associated with improved patient survival N.J. Miller C.D. Church L. Dong D. Crispin M.P. Fitzgibbon K. Lachance L. Jing M. Shinohara I. Gavvovidis G. Willimsky M. McIntosh T. Blankenstein D.M. Koelle P. Nghiem
July 28, 2011 / Blood The only proposed T-cell epitope derived from the TEL-AML1 translocation is not naturally processed J. Popovic L.P. Li P.M. Kloetzel M. Leisegang W. Uckert T. Blankenstein
November 01, 2011 / Eur J Immunol Visualizing the dynamic of adoptively transferred T cells during the rejection of large established tumors J. Charo C. Perez C. Buschow A. Jukica M. Czeh T. Blankenstein
December 13, 2011 / Canc Cell Oncogene-targeting T cells reject large tumors while oncogene inactivation selects escape variants in mouse models of cancer K. Anders C. Buschow A. Herrmann A. Milojkovic C. Loddenkemper T. Kammertoens P. Daniel H. Yu J. Charo T. Blankenstein